Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | TTR | P02766 | 2/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CA3 | P07451 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SELL | P14151 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
| ▸ | FUT4 | P22083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29738542 | 1.00 | CES2 (0.45) | CES2CES1LMNAMAPK1TTR | |
| SCHEMBL628083 | 0.82 | CES2 (0.43) | CES2CES1CA1CA2CA4 | |
| SCHEMBL29234172 | 0.82 | CES1 (0.43) | CES2CES1KIF11 | |
| SCHEMBL28652802 | 0.82 | KIF11 (0.51) | CES2CES1CA5ARXRARXRB | |
| SCHEMBL23526674 | 0.81 | KDM4E (0.40) | TTRCA12CA1CA2CA7 | |
| SCHEMBL20914845 | 0.81 | TPMT (0.42) | TTRHSD17B10HCAR1RXRARXRB | |
| SCHEMBL3230982 | 0.81 | TTR (0.48) | TTRHCAR1SRD5A2KMOTPMT | |
| SCHEMBL19151611 | 0.81 | HDAC1 (0.43) | LMNAMAPK1TTRCA12CA1 | |
| SCHEMBL24275875 | 0.81 | TPMT (0.42) | LMNAMAPK1TTRCA12CA1 | |
| SCHEMBL29624946 | 0.81 | TPMT (0.42) | LMNAMAPK1TTRCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4055016-B1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LTD (GB) | 2026-04-29 | — | — | EP | disclosed |
| US-20230416203-A1 | POTENT AND SELECTIVE INHIBITORS OF THE CALCIUM-ACTIVATED POTASSIUM CHANNEL, KCA3.1, FOR USE AS PLATFORM THERAPEUTICS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2023-12-28 | — | — | US | disclosed |
| EP-4251611-A1 | POTENT AND SELECTIVE INHIBITORS OF THE CALCIUM-ACTIVATED POTASSIUM CHANNEL, Kca3.1, FOR USE AS PLATFORM THERAPEUTICS | Nanyang Technological University (SG) | 2023-10-04 | — | — | EP | disclosed |
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | NXERA PHARMA UK LIMITED (GB) | 2023-01-05 | — | — | US | disclosed |
| EP-4055016-A1 | GPR52 MODULATOR COMPOUNDS | Heptares Therapeutics Limited (GB) | 2022-09-14 | — | — | EP | disclosed |
| WO-2022115043-A1 | POTENT AND SELECTIVE INHIBITORS OF THE CALCIUM-ACTIVATED POTASSIUM CHANNEL, KCa3.1, FOR USE AS PLATFORM THERAPEUTICS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2022-06-02 | — | — | WO | disclosed |
| CN-107667439-B | Formulations comprising organic semiconductors and metal complexes | 默克专利有限公司 | 2021-01-05 | — | — | CN | disclosed |
| CN-107681052-B | Main group metal complexes as p-dopants for organic electronic matrix materials | 西门子公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-03-29 | — | — | US | disclosed |
| EP-2419412-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (BM) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120741-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | IRM LLC (US) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002374-A1 | GPR52 MODULATOR COMPOUNDS | GPR52, GPR119, GPR4 | CES2 2485/4885CES1 1098/4885LMNA 3427/4885 |
| US-20120077854-A1 | COMPOSITIONS AND METHODS FOR MODULATING RETINOL BINDING TO RETINOL BINDING PROTEIN 4 (RBP4) | RBP4, RBP1, FABP4 | CES2 4213/4885CES1 1651/4885LMNA 1913/4885 |
| US-20230416203-A1 | POTENT AND SELECTIVE INHIBITORS OF THE CALCIUM-ACTIVATED POTASSIUM CHANNEL, KCA3.1, FOR USE AS PLATFORM THERAPEUTICS | KCNN3, KCNN1, KCNN2 | CES2 3989/4885CES1 1715/4885LMNA 1096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.